Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GLI1 | P08151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GHSR | Q92847 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20798283 | 0.83 | SCN4A (0.36) | SCN4APRCPDPP7MEN1KMT2A | |
| SCHEMBL29903417 | 0.83 | SCN4A (0.36) | SCN4APRCPDPP7MEN1KMT2A | |
| SCHEMBL2183860 | 0.76 | REN (0.33) | SCN4APRCPDPP7DPP4 | |
| SCHEMBL5495160 | 0.75 | DPP4 (0.34) | SCN4APRCPDPP7DPP4 | |
| SCHEMBL2946688 | 0.75 | DPP4 (0.32) | SCN4APRCPDPP7DPP4 | |
| SCHEMBL28930077 | 0.73 | SCN4A (0.37) | SCN4APRCPDPP7MEN1KMT2A | |
| Isoleucine SCHEMBL1537322 | 0.72 | DPP4 (0.40) | PRCPDPP7NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL15663635 | 0.72 | SCN4A (0.39) | SCN4APRCPDPP7MEN1KMT2A | |
| Isoleucine SCHEMBL138093 | 0.72 | DPP4 (0.40) | PRCPDPP7NOS2NOS3NOS1 | |
| Isoleucine SCHEMBL1537461 | 0.72 | DPP4 (0.40) | PRCPDPP7NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | SCN4A 2143/4885PRCP 78/4885DPP7 373/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | SCN4A 2143/4885PRCP 78/4885DPP7 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.